Author Archives: Stacy Grieve, PhD

NeuroVive Gets Signal That EU Will Give Its Mitochondrial Therapy KL1333 Orphan Drug Status

NeuroVive Pharmaceutical has received a signal from European regulators that its mitochondrial disease therapy KL1333 is likely to receive Orphan Drug Designation, which could accelerate its development and approval. The company is seeking Orphan Drug Designation for KL1333 as treatment for a condition known as mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like…